Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Non-Current Liabilities (2020 - 2022)

Historic Total Non-Current Liabilities for Caribou Biosciences (CRBU) over the last 3 years, with Q4 2022 value amounting to $72.9 million.

  • Caribou Biosciences' Total Non-Current Liabilities rose 3371.61% to $72.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $72.9 million, marking a year-over-year increase of 3371.61%. This contributed to the annual value of $72.9 million for FY2022, which is 3371.61% up from last year.
  • Caribou Biosciences' Total Non-Current Liabilities amounted to $72.9 million in Q4 2022, which was up 3371.61% from $74.7 million recorded in Q3 2022.
  • In the past 5 years, Caribou Biosciences' Total Non-Current Liabilities registered a high of $74.7 million during Q3 2022, and its lowest value of $18.0 million during Q4 2020.
  • For the 3-year period, Caribou Biosciences' Total Non-Current Liabilities averaged around $60.1 million, with its median value being $65.1 million (2021).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 20312.5% in 2021, then skyrocketed by 3014.14% in 2022.
  • Caribou Biosciences' Total Non-Current Liabilities (Quarter) stood at $18.0 million in 2020, then surged by 203.12% to $54.5 million in 2021, then skyrocketed by 33.72% to $72.9 million in 2022.
  • Its Total Non-Current Liabilities stands at $72.9 million for Q4 2022, versus $74.7 million for Q3 2022 and $73.5 million for Q2 2022.